share_log

HC Wainwright & Co. Maintains Buy on BioCryst Pharmaceuticals, Raises Price Target to $19

HC Wainwright & Co. Maintains Buy on BioCryst Pharmaceuticals, Raises Price Target to $19

HC Wainwright公司维持对BioCryst制药公司的买入，将目标价上调至19美元
Benzinga Real-time News ·  2021/03/24 18:38

HC Wainwright & Co. analyst Andrew Fein maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Buy and raises the price target from $14 to $19.

HC Wainwright&Co.分析师安德鲁·费恩(Andrew Fein)表示，BioCryst PharmPharmticals(纳斯达克股票代码：BCRX)，并将目标价从14美元上调至19美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发